RTTNews BiotechCodex · 实盘不做把握 4/10
北京时间·🕒 发布 16:50:16·⟳ 抓取 17:00:34 +10m18s·⚡ 决策 08-18 17:01:53 +1m19s·70.2 天前
诺诚健华Mesutoclax获准在中国启动AML头对头注册III期研究
本次获批把Mesutoclax在AML适应症从早期数据推进到与全球标准疗法头对头的注册III期，方向上利好诺诚健华管线价值。
📄 原文RTTNews Biotech↗ 原文
InnoCare Advances Mesutoclax Into Head-to-Head Phase III AML Trial In China
InnoCare Pharma (INCPF) announced that China's Center for Drug Evaluation has approved a registrational Phase III study…
不做 诺诚健华（09969.HK）
事件方向利好但属于临床III期获批的程序性管线推进，核心疗效数据已在ASCO披露，短期无可量化收入增量且未查得足够高相似先例支持追多。
不做 诺诚健华-U（688428.SH）
A股同一发行人受益逻辑成立，但事件到达时A股已收盘，且该催化缺少新增商业化量级和明确预期差，不满足A股次日追多边界。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- RTTNews报道CDE批准Mesutoclax在中国开展AML注册III期头对头研究，属于本次具体催化的最早可见节点。
- 公司此前已披露Mesutoclax治疗MDS和AML的ASCO口头报告更新数据，说明本次报道中的核心疗效数据不是全新信息。
- 公司已提前发布ASCO摘要关键数据，市场已有两个月时间消化Mesutoclax在AML的有效性叙事。
关键理由
- 本次获批把Mesutoclax在AML适应症从早期数据推进到与全球标准疗法头对头的注册III期，方向上利好诺诚健华管线价值。
- Mesutoclax已是公司血液肿瘤核心全球资产，AML/MDS长期市场空间被公司材料描述为2034年分别约80亿和110亿美元。
- 量级上本事件尚无订单或收入，新增可触达市场仍取决于III期入组、OS优效和后续NDA，短期不能折算为确定收入或利润增量。
主要风险
- 关键疗效数据已在2026年5-6月ASCO阶段公开，本次更多是注册研究获批推进，预期差不够强。
- 药物仍处III期前期，商业化时间远、失败风险和Venetoclax标准疗法竞争仍高，无法形成短线明确正期望。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-06-03 · 影响 weakens
ASCO疗效数据和Mesutoclax作为全球核心资产的叙事已在6月公开，本次新增预期差被削弱。
检索:InnoCare Mesutoclax AML ASCO 2026 prior data Phase III expected 原文 ↗ - 做多前查反向 · 来源 web · 日期 2025-07-14 · 影响 weakens
AML/MDS全球临床推进此前已有公告，本次中国注册研究获批不是全新适应症发现。
检索:InnoCare Mesutoclax AML MDS FDA IND China clinical trials prior announcement 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足和事件相位偏程序性共同压低置信度，最终选择不追多。
方向:同公司Mesutoclax已有BTD、IND和其他注册III期推进公告，但本轮未取得可直接量化的同市场高相似事件价格样本。
涨幅量级:缺少经首发时间和日线锚定验证的高相似样本，不能用先例校准可交易涨幅。
形态:临床III期获批通常是正面研发进展，但若核心数据已提前披露，容易表现为程序性推进而非重估。
原文全文
展开原文 · 2,014 字
InnoCare Pharma (INCPF) announced that China's Center for Drug Evaluation has approved a registrational Phase III study of its novel BCL2 inhibitor Mesutoclax in combination with Azacitidine versus Venetoclax with Azacitidine in elderly or unfit patients with treatment-naive acute myeloid leukemia.
Acute myeloid leukemia (AML) is a malignant blood cancer that becomes more common with age, and treatment options for older or unfit patients remain limited.
Mesutoclax, an orally bioavailable BCL2-selective inhibitor, works by restoring the normal process of apoptosis in cancer cells. The Phase III trial is designed to demonstrate superiority in overall survival compared to the current global standard of care, Venetoclax plus Azacitidine.
Earlier data presented at the 2026 ASCO Annual Meeting showed promising results: 81.8% of evaluable patients achieved composite complete remission (CR+CRi), with 86.5% of responders testing negative for minimal residual disease. Notably, 83% of complete responders achieved remission in the first treatment cycle, and both 30-day and 60-day mortality rates were 0%. At the recommended dose, the six-month overall survival rate reached 90.5%.
Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, emphasized that the efficacy and safety demonstrated so far give confidence to test Mesutoclax head-to-head against the global standard. She noted that Mesutoclax is one of the company's key global assets, with trials already enrolling patients in the U.S. and Australia.
9969.HK has traded between HKD 9.65 and HKD 20.62 over the past year. The stock is currently trading at HKD 14.67, up 0.27%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 15, 2026 03:28 ET Inflation and consumer spending figures were the main economic news from the U.S. this week, along with some data on the housing market. In Europe, the second quarter economic growth figures were in focus. The Australian central bank policy decision drew attention in Asia.
Acute myeloid leukemia (AML) is a malignant blood cancer that becomes more common with age, and treatment options for older or unfit patients remain limited.
Mesutoclax, an orally bioavailable BCL2-selective inhibitor, works by restoring the normal process of apoptosis in cancer cells. The Phase III trial is designed to demonstrate superiority in overall survival compared to the current global standard of care, Venetoclax plus Azacitidine.
Earlier data presented at the 2026 ASCO Annual Meeting showed promising results: 81.8% of evaluable patients achieved composite complete remission (CR+CRi), with 86.5% of responders testing negative for minimal residual disease. Notably, 83% of complete responders achieved remission in the first treatment cycle, and both 30-day and 60-day mortality rates were 0%. At the recommended dose, the six-month overall survival rate reached 90.5%.
Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, emphasized that the efficacy and safety demonstrated so far give confidence to test Mesutoclax head-to-head against the global standard. She noted that Mesutoclax is one of the company's key global assets, with trials already enrolling patients in the U.S. and Australia.
9969.HK has traded between HKD 9.65 and HKD 20.62 over the past year. The stock is currently trading at HKD 14.67, up 0.27%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 15, 2026 03:28 ET Inflation and consumer spending figures were the main economic news from the U.S. this week, along with some data on the housing market. In Europe, the second quarter economic growth figures were in focus. The Australian central bank policy decision drew attention in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。